FDA approval for novel breast cancer drug granted ahead of anticipated target date
the ONA take:
The US Food and Drug Administration granted accelerated approved for palbociclib (Ibrance) for the treatment of advanced breast cancer in postmenopausal women whose tumors do not express HER2 protein.
Palbociclib blocks molecules linked to cancer cell growth; it is intended for use in combination with letrozole. Designated as a breakthrough drug in 2014, approval was granted 2 months ahead of its April 13 target date. A 165-patient study showed that palbociclib slowed the progression of breast cancer.
Patients taking palbociclib and letrozole lived 20.2 months on average before their tumors worsened. The most common side effects reported were low white blood cell count, fatigue, nausea, hair loss, diarrhea, vomiting, and nerve damage. The drug is manufactured by Pfizer Inc.
The FDA granted accelerated approved for palbociclib (Ibrance) for the treatment of advanced breast cancer.
- Sexual Dysfunction in Women With Cancer: A Review of Available Interventions
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
- Worse Survival Seen for Alternative Versus Usual Cancer Therapy
- Anorexia-Cachexia in Non-Small Cell Lung Cancer Improved With Anamorelin
- Early Recognition of Checkpoint Inhibitor-Related Pneumonitis Improves Outcomes
- Lenalidomide After ASCT Prolongs Time to Progression in Multiple Myeloma
- Arthritis Medication Shows Potential in the Treatment of Polycythemia Vera
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|